{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03502967: Early Phase 1 Interventional Enrolling by invitation Traumatic Brain Injury
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:amdakefalin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04586335: Phase 1 Interventional Terminated Ovarian Cancer
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Upenazime is a non-radioactive chemical precursor for diagnostic imaging.
Status:
Investigational
Source:
NCT03891524: Phase 2 Interventional Completed Arthroplasty, Replacement, Knee
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:chlorazodin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Chloroazodin is aliphatic chloramine derivative with potent antiseptic action effective against many microörganisms, fungi, yeast, and plasmodia, with a low toxicity
Status:
Investigational
Source:
NCT02784444: Phase 2 Interventional Completed Non-alcoholic Fatty Liver Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
MSDC 0602, a first-in-class oral, once-daily, insulin sensitiser that acts by stimulating mitochondrial proteins, is being developed by Metabolic Solutions and Cirius Therapeutics for treatment Type 2 diabetes mellitus and Non-alcoholic steatohepatitis. MSDC-0602 prevented and reversed liver fibrosis and suppressed expression of markers of stellate cell activation in livers of mice fed a diet rich in trans-fatty acids, fructose, and cholesterol. Moreover, mice with liver-specific deletion of MPC2 were protected from development of NASH on this diet. MSDC-0602 directly reduced hepatic stellate cell activation in vitro, and MSDC-0602 treatment or hepatocyte MPC2 deletion also limited stellate cell activation indirectly by affecting secretion of exosomes from hepatocytes. Cirius Therapeutics plans the phase III trial for Type 2 diabetes mellitus and Non-alcoholic steatohepatitis in September 2019
Status:
Investigational
Source:
NCT04258462: Phase 2 Interventional Recruiting Benign Kidney Neoplasm
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:bemnifosbuvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
